4.7 Article

Illness Progression, Recent Stress, and Morphometry of Hippocampal Subfields and Medial Prefrontal Cortex in Major Depression

Journal

BIOLOGICAL PSYCHIATRY
Volume 77, Issue 3, Pages 285-294

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2014.06.018

Keywords

Dentate gyrus; Hippocampus; MAGeT brain; Major depression; mPFC; MRI

Funding

  1. National Institute of Mental Health (NIMH) [R01 MH068376]
  2. National Center for Complementary and Alternative Medicine (NCCAM) [R21 AT002974]
  3. NCCAM [R01 AT001638]
  4. NIMH [K01 MH099232, K99 MH094438]
  5. W. Garfield Weston Foundation
  6. Icahn School of Medicine at Mount Sinai from AstraZeneca
  7. Brainsway
  8. Euthymics Bioscience, Inc.
  9. NeoSync
  10. Roche
  11. Shire
  12. Avanir Pharmaceuticals
  13. CNS Response, Inc.
  14. Otsuka
  15. Servier
  16. Sunovion
  17. Abbott Laboratories
  18. Alkermes, Inc.
  19. American Cyanamid
  20. Aspect Medical Systems
  21. AstraZeneca
  22. BioResearch
  23. BrainCells, Inc.
  24. Bristol-Myers Squibb
  25. CeNeRx BioPharma
  26. Cephalon
  27. Clintara LLC
  28. Covance
  29. Covidien
  30. Eli Lilly
  31. Company
  32. EnVivo Pharmaceuticals Inc.
  33. Forest Pharmaceuticals, Inc.
  34. Ganeden Biotech, Inc.
  35. GlaxoSmithKline
  36. Harvard Clinical Research Institute
  37. Hoffmann-La Roche
  38. Icon Clinical Research
  39. i3 Innovus/Ingenix
  40. Janssen RD LLC
  41. Jed Foundation
  42. Johnson & Johnson Pharmaceutical Research Development
  43. Lichtwer Pharma GmbH
  44. Lorex Pharmaceuticals
  45. MedAvante
  46. National Alliance for Research on Schizophrenia and Depression
  47. National Center for Complementary and Alternative Medicine
  48. National Institute of Drug Abuse
  49. National Institute of Mental Health, Neuralstem, Inc.
  50. Novartis AG
  51. Organon Pharmaceuticals
  52. Pamlab LLC
  53. Pfizer, Inc.
  54. Pharmacia-Upjohn
  55. Pharmaceutical Research Associates, Inc.
  56. Pharmavite LLC
  57. PharmoRx Therapeutics
  58. Photothera
  59. RCT Logic LLC
  60. Sanofi
  61. Solvay Pharmaceuticals, Inc.
  62. Synthelabo
  63. Wyeth-Ayerst Laboratories
  64. Affectis Pharmaceuticals AG
  65. Amarin Pharma, Inc.
  66. Auspex Pharmaceuticals
  67. Bayer
  68. Best Practice Project Management, Inc.
  69. BioMarin Pharmaceutical, Inc.
  70. Biovail Corporation
  71. Cephalon, Inc.
  72. Cerecor
  73. Clinical Trials Solutions
  74. Compellis Pharmaceuticals
  75. Cypress Pharmaceutical, Inc.
  76. DiagnoSearch Life Sciences Pvt Ltd.
  77. Dainippon Sumitomo Pharma Co., Inc.
  78. DOV Pharmaceuticals, Inc.
  79. Edgemont Pharmaceuticals, Inc.
  80. Eisai, Inc.
  81. Eli Lilly and Company
  82. EnVivo Pharmaceuticals, Inc.
  83. ePharmaSolutions
  84. EPIX Pharmaceuticals, Inc.
  85. Fabre-Kramer Pharmaceuticals, Inc.
  86. Genomind LLC
  87. Grunenthal GmbH
  88. i3 Innovus/Ingenis
  89. Janssen Pharmaceutica
  90. Jazz Pharmaceuticals, Inc.
  91. Johnson & Johnson Pharmaceutical Research & Development LLC
  92. Knoll Pharmaceuticals Corp.
  93. Labopharm, Inc.
  94. Lundbeck, Inc.
  95. MedAvante Inc.
  96. Merck Co., Inc.
  97. MSI Methylation Sciences, Inc.
  98. Naurex, Inc.
  99. Neuralstem, Inc.
  100. Neuronetics, Inc.
  101. NextWave Pharmaceuticals
  102. Nutrition 21
  103. Orexigen Therapeutics, Inc.
  104. Otsuka Pharmaceuticals
  105. PharmaStar
  106. Precision Human Biolaboratory
  107. Prexa Pharmaceuticals, Inc.
  108. Puretech Ventures
  109. PsychoGenics
  110. Psylin Neurosciences, Inc.
  111. Rexahn Pharmaceuticals, Inc.
  112. Ridge Diagnostics, Inc.
  113. Sepracor, Inc.
  114. Servier Laboratories
  115. Schering-Plough Corporation
  116. Somaxon Pharmaceuticals, Inc.
  117. Somerset Pharmaceuticals
  118. Sunovion Pharmaceuticals
  119. Supernus Pharmaceuticals, Inc.
  120. Takeda Pharmaceutical Company Limited
  121. Tal Medical, Inc.
  122. Tetragenex Pharmaceuticals, Inc.
  123. TransForm Pharmaceuticals, Inc.
  124. Transcept Pharmaceuticals, Inc.
  125. Vanda Pharmaceuticals, Inc.
  126. Advanced Neuro Technology North America
  127. Ono Pharma USA
  128. Pfizer

Ask authors/readers for more resources

BACKGROUND: Longitudinal studies of illness progression in patients with major depressive disorder (MDD) indicate that the onset of subsequent depressive episodes becomes increasingly decoupled from external stressors. A possible mechanism underlying this phenomenon is that multiple episodes induce long-lasting neurobiological changes that confer increased risk for recurrence. Prior morphometric studies have frequently reported volumetric reductions in patients with MDD-especially in medial prefrontal cortex (mPFC) and the hippocampus-but few studies have investigated whether these changes are exacerbated by prior episodes. METHODS: In a sample of 103 medication-free patients with depression and control subjects with no history of depression, structural magnetic resonance imaging was performed to examine relationships between number of prior episodes, current stress, hippocampal subfield volume and cortical thickness. Volumetric analyses of the hippocampus were performed using a recently validated subfield segmentation approach, and cortical thickness estimates were obtained using vertex-based methods. Participants were grouped on the basis of the number of prior depressive episodes and current depressive diagnosis. RESULTS: Number of prior episodes was associated with both lower reported stress levels and reduced volume in the dentate gyrus. Cortical thinning of the left mPFC was associated with a greater number of prior depressive episodes but not current depressive diagnosis. CONCLUSIONS: Collectively, these findings are consistent with preclinical models suggesting that the dentate gyrus and mPFC are especially vulnerable to stress exposure and provide evidence for morphometric changes that are consistent with stress-sensitization models of recurrence in MDD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available